Skip to main content

Table 3 Mortality (28-day) in tifacogin and placebo groups for all patients and by microbiology status and heparin use

From: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

  Tifacogin Placebo P value
  All Mortality All Mortality  
  Number Number Percentage Number Number Percentage  
All community-acquired pneumonia patients 251 70 27.9 245 80 32.7 0.25
Microbiology status
   Organism identified 170 46 27.1 154 55 35.7 0.09
   Organism not identified 81 24 29.6 91 25 27.5 0.75
Procalcitonin level
   <2 50 15 30.0 60 18 30.0 1.00
   ≥ 2 200 55 27.5 183 62 33.9 0.18
Heparin use
   No Heparin 79 23 29.1 78 33 42.3 0.08
   Heparin 172 47 27.3 167 47 28.1 0.87
Microbiology status and heparin use
   No heparin/Organism identified 58 17 29.3 54 28 51.9 0.02
   No heparin/Organism not identified 21 6 28.6 24 5 20.8 0.54
Shock
   Yes 163 50 30.7 176 64 36.4 0.27
   No 88 20 22.7 69 16 23.2 0.95
Ventilatory support
   Yes 193 60 31.1 200 75 37.5 0.18
   No 58 10 17.2 45 5 11.1 0.38
Number of organ dysfunctions
   Two or less 87 17 19.5 72 13 18.1 0.81
   Three or more 164 53 32.3 173 67 38.7 0.22